Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells $49,904.10 in Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO William Garrett Gray sold 12,322 shares of the firm’s stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $4.05, for a total value of $49,904.10. Following the completion of the sale, the chief financial officer now owns 1,446,322 shares in the company, valued at $5,857,604.10. The trade was a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

William Garrett Gray also recently made the following trade(s):

• On Thursday, February 6th, William Garrett Gray sold 74,110 shares of Checkpoint Therapeutics stock. The stock was sold at an average price of $3.67, for a total transaction of $271,983.70.

Checkpoint Therapeutics Trading Down 0.7 %

CKPT stock opened at $4.01 on Friday. The firm’s 50-day moving average is $3.42 and its two-hundred day moving average is $3.32. The company has a market capitalization of $195.82 million, a price-to-earnings ratio of -2.18 and a beta of 1.21. Checkpoint Therapeutics, Inc. has a 52 week low of $1.38 and a 52 week high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its earnings results on Friday, March 28th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.47). The company had revenue of $0.04 million during the quarter. On average, equities research analysts predict that Checkpoint Therapeutics, Inc. will post -0.94 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on CKPT shares. D. Boral Capital restated a “buy” rating and issued a $4.80 price target on shares of Checkpoint Therapeutics in a research note on Monday, March 31st. Lake Street Capital reaffirmed a “hold” rating and set a $4.10 target price (down previously from $7.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th. Finally, HC Wainwright reissued a “neutral” rating and issued a $4.10 price target on shares of Checkpoint Therapeutics in a research note on Tuesday, March 11th.

Institutional Trading of Checkpoint Therapeutics

Several institutional investors have recently modified their holdings of the company. SBI Securities Co. Ltd. bought a new stake in Checkpoint Therapeutics in the fourth quarter worth about $32,000. State Street Corp grew its stake in shares of Checkpoint Therapeutics by 32.2% in the 3rd quarter. State Street Corp now owns 94,424 shares of the company’s stock worth $212,000 after purchasing an additional 23,000 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Checkpoint Therapeutics by 41.2% in the 3rd quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock worth $958,000 after purchasing an additional 124,787 shares in the last quarter. Virtu Financial LLC lifted its stake in Checkpoint Therapeutics by 180.5% during the fourth quarter. Virtu Financial LLC now owns 38,157 shares of the company’s stock valued at $122,000 after purchasing an additional 24,552 shares during the last quarter. Finally, Walleye Capital LLC acquired a new stake in Checkpoint Therapeutics during the third quarter valued at approximately $148,000. Institutional investors and hedge funds own 22.00% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.